Drug Trial Radar · NCT01716975
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Last checked: Nov 20, 2026Latest source record: May 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
767
Actual
Start
Oct 2012
Primary completion
Feb 2016
Study completion Feb 2016
Sponsor
- Lead sponsor
- FORUM Pharmaceuticals IncIndustry
- Sponsor type
- Industry
- Collaborators
- Syneos Health; NeuroCog Trials, Inc.
- First posted
- Oct 30, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
Conditions
- Schizophrenia
- Impaired Cognition
Interventions
EVP-6124Drug
Arms 1, 2
PlaceboDrug
Arm 3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) to Day 182Time frame: Baseline to Day 182 or Early Termination
- Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182Time frame: Baseline to Day 182 or Early Termination
- Safety and Tolerability of EVP-6124 or Placebo in Subjects with SchizophreniaTime frame: Screening (Day -42 to Day -15) to Day 182 or Early Terminiation
Locations
106 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Phoenixville, Arizona
Site not named
Little Rock, Arkansas
Site not named
Cerritos, California
Site not named
Chino, California
Site not named
Costa Mesa, California
Site not named
Garden Grove, California
Site not named
Glendale, California
Site not named
Norwalk, California
Site not named
Oakland, California
Site not named
Oakland Park, California
Site not named
Oceanside, California
Site not named
Riverside, California
Site not named
San Diego, California
Site not named
San Gabriel, California
Site not named
Santa Ana, California
Site not named
Sherman Oaks, California
Site not named
Washington D.C., District of Columbia
Site not named
Bradenton, Florida
Site not named
Miami, Florida
Site not named
Miami Springs, Florida
Site not named
North Miami, Florida
Site not named
Orlando, Florida
Site not named
Marietta, Georgia
Site not named
Smyrna, Georgia
Site not named
Chicago, Illinois
Site not named
Oak Brook, Illinois
Site not named
Oak Park, Illinois
Site not named
Wichita, Kansas
Site not named
Lake Charles, Louisiana
Site not named
Shreveport, Louisiana
Site not named
Rockville, Maryland
Site not named
Boston, Massachusetts
Site not named
Saint Charles, Missouri
Site not named
St Louis, Missouri
Site not named
Lincoln, Nebraska
Site not named
Princeton, New Jersey
Site not named
Jamaica, New York
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Charlotte, North Carolina
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.